UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Stake in Integra LifeSciences Holdings Co. (NASDAQ:IART)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 0.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 170,185 shares of the life sciences company’s stock after selling 466 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Integra LifeSciences were worth $3,092,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. FORA Capital LLC purchased a new stake in shares of Integra LifeSciences in the 3rd quarter worth approximately $436,000. MetLife Investment Management LLC grew its stake in shares of Integra LifeSciences by 129.1% in the third quarter. MetLife Investment Management LLC now owns 39,638 shares of the life sciences company’s stock worth $720,000 after acquiring an additional 22,334 shares during the last quarter. Rubric Capital Management LP bought a new position in shares of Integra LifeSciences during the third quarter valued at $5,325,000. Glenmede Trust Co. NA raised its position in shares of Integra LifeSciences by 125.9% in the 3rd quarter. Glenmede Trust Co. NA now owns 727,781 shares of the life sciences company’s stock worth $13,224,000 after purchasing an additional 405,624 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in Integra LifeSciences by 824.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 111,775 shares of the life sciences company’s stock worth $2,031,000 after purchasing an additional 99,685 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

Insider Transactions at Integra LifeSciences

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the sale, the executive vice president now directly owns 56,182 shares of the company’s stock, valued at $1,357,357.12. This represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.10% of the stock is currently owned by company insiders.

Integra LifeSciences Stock Down 0.9 %

Integra LifeSciences stock opened at $24.03 on Friday. Integra LifeSciences Holdings Co. has a one year low of $16.81 and a one year high of $45.42. The stock has a fifty day moving average of $22.12 and a 200 day moving average of $23.76. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The stock has a market cap of $1.85 billion, a PE ratio of -267.00, a price-to-earnings-growth ratio of 0.82 and a beta of 1.15.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $380.80 million for the quarter, compared to analysts’ expectations of $375.81 million. During the same quarter in the prior year, the business earned $0.76 EPS. The business’s quarterly revenue was down .4% on a year-over-year basis. As a group, sell-side analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Bank of America decreased their target price on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Citigroup upped their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research report on Tuesday, November 5th. Truist Financial reduced their target price on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a report on Monday, October 14th. BTIG Research raised Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Finally, Morgan Stanley began coverage on Integra LifeSciences in a report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price objective for the company. Three analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, Integra LifeSciences presently has a consensus rating of “Hold” and a consensus target price of $23.00.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.